Nuwellis, Inc.
NUWE Healthcare Medical Devices
Nuwellis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.3 million, down 5.38% from fiscal 2024. In the quarter to June 2026, revenue grew 14.1%, EPS grew 98.8% and free cash flow fell 51.6%, each against the same quarter a year earlier.
Follow NUWE
Nuwellis, Inc. (NUWE) EV/Sales
As of 16 October 2026, Nuwellis, Inc. (NUWE) trades at a EV/Sales of 0.0×. Over the past ten years it has ranged from −2.6× (March 2022) to 357,124,351,397,036× (February 2015); the current reading is higher than 17% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.5× | 1,215.24% |
| FY2024 | 0.0× | 116.18% |
| FY2023 | 0.0× | — |
| FY2022 | −1.7× | — |
| FY2021 | −2.6× | — |
| FY2020 | 7,947,077× | 307.33% |
| FY2019 | 1,951,011× | (97.72%) |
| FY2018 | 85,588,590× | (17.65%) |
| FY2017 | 103,927,550× | (98.94%) |
| FY2016 | 9,819,696,212× | (99.67%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.1× | (85.97%) |
| Mar 2026 | 0.5× | (6.12%) |
| Dec 2025 | 0.5× | 9.75% |
| Sep 2025 | 0.4× | 164.27% |
| 37 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NUVOQ Holdco Nuvo Group D.G Ltd. compare | n/m |
| NUWE Nuwellis, Inc. | 0.0× |
| DHAI DIH Holding US, Inc. compare | 0.1× |
| BIOLQ Biolase, Inc. compare | 0.3× |
| AFIB Acutus Medical, Inc. compare | 0.9× |
| XAIR Beyond Air, Inc. compare | 1.1× |
| VJET Flyte Aviation, Inc. compare | 2.1× |
| NXL Nexalin Technology, Inc. compare | 3.0× |
| ADGM Adagio Medical Holdings, Inc. compare | 32.1× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)